The 50/50 Deal Nobody is Modeling Correctly

Moderna and Merck announced positive Phase 3 INTerpath-001 results for intismeran autogene plus Keytruda in resected Stage IIB-IV melanoma. Both primary endpoints were met: recurrence-free survival and distant metastasis-free survival. The trial was stopped early after the first prespecified interim analysis. This is the first positive Phase 3 for a personalized neoantigen therapy and the first for any mRNA-based cancer treatment.

On August 19, 2026, shares moved from 62.96 into the low 140s pre-market, more than doubling. The market has priced in melanoma success. The market has not priced in what the sell-side is about to do to its models over the next 48 to 72 hours.

Moderna and Merck operate under a 50/50 profit-sharing collaboration, executed October 2022 when Merck exercised its option for 250 million dollars. Original 2016 upfront: 200 million. Both companies share worldwide development costs and profits equally.

The accounting matters. Under ASC 808, Moderna will book its 50 percent share of net profit as revenue, not gross end-market sales. Reported "Cancer Vaccines Pipeline" revenue on Moderna's income statement will therefore understate the commercial franchise by roughly half.

Consensus Cancer Vaccines Pipeline peaks at 1,627M in 2035E per the current estimate stack. That number implies end-market sales of roughly 3B to 4B at plausible margins. Bull case at the current High estimate implies end-market peak sales north of 5B.

Sixteen brokers cover MRNA. Seventeen named analysts. Entering today, 22 of 24 ratings were Hold or worse and the consensus 12-month price target was 55.12, a discount to the pre-news price.

Cash breakeven is targeted for 2028. GAAP profitability crosses in 2030E. Consensus embedded roughly 50 to 55 percent probability of Phase 3 success in the Cancer Vaccines Pipeline line. That probability now moves to 90-plus.

Vintage estimate data shows the first-mover revisions have already flowed in. FY2030 EPS estimate movement over time:

That is a 4.66-dollar lift in FY2030 EPS in the last 30 days alone. FY2029 EPS moved from -0.88 to +1.59 in the same window, a 2.47-dollar lift. FY2030 revenue moved from 6,923M to 7,541M, up 618M.

Over the last 2 to 3 months: 11 raised, 0 cut. Zero downside revisions across the entire cycle. William Blair took the stock to Outperform from Market Perform today.

The revision breadth is one-directional and the magnitude is accelerating.

The mechanical adjustments the sell-side has to run:

Pre-news consensus 12-month mean price target: 55.12. Number of contributing analysts: 19.

The revision cascade forces the mean PT toward the analytical range implied by current and post-revision forward numbers. Applying a 25x forward multiple to normalized EPS on a 4-year forward view, discounted back at 10 percent:

Cross-check via EV/Revenue: at the 140 level reached on August 19, enterprise value is roughly 55B. FY2030E revenue at consensus 4.8B implies 11.5x forward EV/revenue on a 4-year view. Growth-biotech peer range is 8 to 12x. The stock sits at the high end of peer-fair on this metric.

Cross-check via SOTP: prophylactic franchise NPV ~5.5B, melanoma at 90 percent PoS ~7B PV, other tumors at blended 30 percent PoS ~8B PV, net cash burn adjustment negative 6B through 2029. Sum ~14.5B divided by ~410M post-dilution diluted shares implies 35 per share. This is why traditional SOTP models produce Hold ratings on MRNA. Post-catalyst, the PoS adjustment on other tumor indications is the swing variable.

Where consensus mean PT should migrate over the next 30 days: 100 to 135 range as the risk-adjusted revenue lines get repriced. Bull case skew adds M&A optionality that would clear above standalone fair value.

Merck faces its Keytruda LOE in 2028. The 50/50 structure on intismeran was appropriate when the asset was optionality. Post-validation, the split economics create pressure to consolidate. Merck has the commercial infrastructure, the KOL relationships, the payer contracts. Moderna owns half the profit stream of a validated 3B-plus franchise with platform optionality.

The question is not whether the current structure gets renegotiated. It is whether Merck offers to buy Moderna's 50 percent share of intismeran, or the entire company. Either transaction would be immediately accretive to Merck.

This is now a live M&A candidate. The strategic logic is unambiguous.

The trial data has not yet been peer-reviewed or presented in full. Detailed efficacy metrics come at a future medical meeting. Hazard ratios matter for label. Overall survival data is still maturing.

Regulatory path timing is uncertain. Accelerated approval is possible but not guaranteed.

Manufacturing scale-up for personalized vaccines is nontrivial. Each dose is custom-produced from a patient tumor sample. Gross margin expansion depends on Moderna solving personalized manufacturing at commercial scale.

Post-readout, sell-side revision breadth becomes crowded. The alpha in the estimate re-rate compresses as coverage catches up.